Novo Nordisk A/S shares are staging a comeback after a tumultuous year for the maker of Ozempic and Wegovy. The stock is up ...

Novo Nordisk has rebounded strongly in 2025, backed by solid financials despite earlier setbacks and competitive risks. See ...

Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...

Eli Lilly ( LLY 0.90%) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following ...

Denmark's Novo Nordisk is partnering with biotech company Deep Apple Therapeutics in a deal worth up to $812 million to ...

Gov. Josh Shapiro’s administration plans to save money by cutting poor patients’ access to expensive weight-loss drugs like ...

On top of that, an analyst cut his price target on the Denmark-based pharmaceutical company. Novo Nordisk (NYSE: NVO) stock ...

A trial pitting weight loss jab Mounjaro against competitor Wegovy ended with one clear winner, and Mounjaro is getting ...

Deep Apple Therapeutics, Inc. announced on Wednesday a research collaboration and exclusive worldwide license agreement with ...

Novo Nordisk will begin phase 3 trials for amycretin in early 2026 following promising weight loss data and regulatory ...

Wegovy maker Novo Nordisk has hired the start-up Deep Apple Therapeutics to develop small molecules as its next weight-loss ...

Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early ...